Freedom Broker Initiates Coverage of AngioDynamics (ANGO) with Buy Recommendation

Freedom Broker initiated coverage of AngioDynamics (NasdaqGS: ANGO) with a Buy on April 6, 2026, issuing a price forecast that implies a 103.30% upside. The initiation and very large implied upside is strongly positive for ANGO shares and may drive near-term buying interest, though the effect is likely confined to the individual stock rather than the broader market.

Analysis

Freedom Broker initiated coverage of AngioDynamics (NasdaqGS: ANGO) with a Buy on April 6, 2026, issuing a price forecast that implies a 103.30% upside. The initiation and very large implied upside is strongly positive for ANGO shares and may drive near-term buying interest, though the effect is likely confined to the individual stock rather than the broader market.